157 related articles for article (PubMed ID: 22986363)
1. Pramipexole upregulates dopamine receptor D₂ and D₃ expression in rat striatum.
Tokunaga N; Choudhury ME; Nishikawa N; Nagai M; Tujii T; Iwaki H; Kaneta M; Nomoto M
J Pharmacol Sci; 2012; 120(2):133-7. PubMed ID: 22986363
[TBL] [Abstract][Full Text] [Related]
2. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.
Castro-Hernández J; Afonso-Oramas D; Cruz-Muros I; Salas-Hernández J; Barroso-Chinea P; Moratalla R; Millan MJ; González-Hernández T
Neurobiol Dis; 2015 Feb; 74():325-35. PubMed ID: 25511804
[TBL] [Abstract][Full Text] [Related]
3. Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients.
Deutschländer A; la Fougère C; Boetzel K; Albert NL; Gildehaus FJ; Bartenstein P; Xiong G; Cumming P
Neuroimage Clin; 2016; 12():41-6. PubMed ID: 27408789
[TBL] [Abstract][Full Text] [Related]
4. Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats.
Breuer ME; Groenink L; Oosting RS; Buerger E; Korte M; Ferger B; Olivier B
Eur J Pharmacol; 2009 Aug; 616(1-3):134-40. PubMed ID: 19549514
[TBL] [Abstract][Full Text] [Related]
5. High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum.
Piercey MF; Walker EL; Feldpausch DL; Camacho-Ochoa M
Neurosci Lett; 1996 Nov; 219(2):138-40. PubMed ID: 8971799
[TBL] [Abstract][Full Text] [Related]
6. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
[TBL] [Abstract][Full Text] [Related]
7. Reinforcing properties of Pramipexole in normal and parkinsonian rats.
Engeln M; Ahmed SH; Vouillac C; Tison F; Bezard E; Fernagut PO
Neurobiol Dis; 2013 Jan; 49():79-86. PubMed ID: 22940424
[TBL] [Abstract][Full Text] [Related]
8. In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors.
Fenu S; Espa E; Pisanu A; Di Chiara G
Eur J Pharmacol; 2016 Oct; 788():183-191. PubMed ID: 27343381
[TBL] [Abstract][Full Text] [Related]
9. Effects of pramipexole on the duration of immobility during the forced swim test in normal and ACTH-treated rats.
Kitagawa K; Kitamura Y; Miyazaki T; Miyaoka J; Kawasaki H; Asanuma M; Sendo T; Gomita Y
Naunyn Schmiedebergs Arch Pharmacol; 2009 Jul; 380(1):59-66. PubMed ID: 19274453
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.
Piercey MF; Hoffmann WE; Smith MW; Hyslop DK
Eur J Pharmacol; 1996 Sep; 312(1):35-44. PubMed ID: 8891576
[TBL] [Abstract][Full Text] [Related]
11. Striatal changes underlie MPEP-mediated suppression of the acquisition and expression of pramipexole-induced place preference in an alpha-synuclein rat model of Parkinson's disease.
Loiodice S; McGhan P; Gryshkova V; Fleurance R; Dardou D; Hafidi A; Nogueira da Costa A; Durif F
J Psychopharmacol; 2017 Oct; 31(10):1323-1333. PubMed ID: 28631520
[TBL] [Abstract][Full Text] [Related]
12. [Effects of hemantane on the main subtypes of dopamine receptors in the rat striatum ex vivo].
Abaimov DA; Zimin IA; Kovalev GI
Eksp Klin Farmakol; 2008; 71(1):18-21. PubMed ID: 18365481
[TBL] [Abstract][Full Text] [Related]
13. Behavioral sensitization to cocaine in rats: evidence for temporal differences in dopamine D3 and D2 receptor sensitivity.
Collins GT; Truong YN; Levant B; Chen J; Wang S; Woods JH
Psychopharmacology (Berl); 2011 Jun; 215(4):609-20. PubMed ID: 21207013
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease.
Holtz NA; Tedford SE; Persons AL; Grasso SA; Napier TC
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Oct; 70():77-84. PubMed ID: 27216282
[TBL] [Abstract][Full Text] [Related]
15. Low dose pramipexole causes D3 receptor-independent reduction of locomotion and responding for a conditioned reinforcer.
McCormick PN; Fletcher PJ; Wilson VS; Browne JD; Nobrega JN; Remington GJ
Neuropharmacology; 2015 Feb; 89():225-31. PubMed ID: 25283483
[TBL] [Abstract][Full Text] [Related]
16. The discriminative stimulus effects of dopamine D2- and D3-preferring agonists in rats.
Koffarnus MN; Greedy B; Husbands SM; Grundt P; Newman AH; Woods JH
Psychopharmacology (Berl); 2009 Apr; 203(2):317-27. PubMed ID: 18807248
[TBL] [Abstract][Full Text] [Related]
17. The dopamine D1 receptor agonist, but not the D2 receptor agonist, induces gene expression of Homer 1a in rat striatum and nucleus accumbens.
Yamada H; Kuroki T; Nakahara T; Hashimoto K; Tsutsumi T; Hirano M; Maeda H
Brain Res; 2007 Feb; 1131(1):88-96. PubMed ID: 17169339
[TBL] [Abstract][Full Text] [Related]
18. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.
Seeman P; Ko F; Willeit M; McCormick P; Ginovart N
Synapse; 2005 Nov; 58(2):122-8. PubMed ID: 16088951
[TBL] [Abstract][Full Text] [Related]
19. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
Mierau J; Schneider FJ; Ensinger HA; Chio CL; Lajiness ME; Huff RM
Eur J Pharmacol; 1995 Jun; 290(1):29-36. PubMed ID: 7664822
[TBL] [Abstract][Full Text] [Related]
20. The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study.
Ferger B; Teismann P; Mierau J
Brain Res; 2000 Nov; 883(2):216-23. PubMed ID: 11074050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
